V
31.53
-0.41 (-1.28%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | Veracyte, Inc. | Bullish | Bullish |
Stockmoo Score
-1.1
|
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 37.00 (Needham, 17.35%) | Buy |
| Median | 31.50 (-0.10%) | |
| Low | 26.00 (Morgan Stanley, -17.54%) | Sell |
| Average | 31.50 (-0.10%) | |
| Total | 1 Buy, 1 Sell | |
| Avg. Price @ Call | 30.77 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 28 Aug 2024 | 37.00 (17.35%) | Buy | 31.62 |
| Morgan Stanley | 12 Aug 2024 | 26.00 (-17.54%) | Sell | 29.92 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CHAMBERS REBECCA | - | 31.55 | -3,464 | -109,289 |
| LEITE JOHN | - | 30.55 | -6,794 | -203,393 |
| MCGUIRE ANNIE | - | 31.55 | -1,920 | -60,576 |
| MILLER THOMAS F. | 30.29 | - | 16,507 | 499,997 |
| SHAFER DAVID BRENT | 30.29 | - | 16,507 | 499,997 |
| STAPLEY MARC | - | 31.55 | -5,748 | -181,349 |
| WYGANT JONATHAN | - | 31.55 | -1,087 | -34,295 |
| Aggregate Net Quantity | 14,001 | |||
| Aggregate Net Value ($) | 411,092 | |||
| Aggregate Avg. Buy ($) | 30.29 | |||
| Aggregate Avg. Sell ($) | 31.22 | |||
| Insider Range ($) | ||||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| LEITE JOHN | Officer | 04 Sep 2024 | Automatic sell (-) | 5,479 | 29.55 | 161,904 |
| MILLER THOMAS F. | Director | 03 Sep 2024 | Acquired (+) | 16,507 | 30.29 | 499,997 |
| SHAFER DAVID BRENT | Director | 03 Sep 2024 | Acquired (+) | 16,507 | 30.29 | 499,997 |
| WYGANT JONATHAN | Officer | 02 Sep 2024 | Disposed (-) | 1,087 | 31.55 | 34,295 |
| LEITE JOHN | Officer | 02 Sep 2024 | Disposed (-) | 1,315 | 31.55 | 41,488 |
| STAPLEY MARC | Officer | 02 Sep 2024 | Disposed (-) | 5,748 | 31.55 | 181,349 |
| MCGUIRE ANNIE | Officer | 02 Sep 2024 | Disposed (-) | 1,920 | 31.55 | 60,576 |
| CHAMBERS REBECCA | Officer | 02 Sep 2024 | Disposed (-) | 3,464 | 31.55 | 109,289 |
| Date | Type | Details |
|---|---|---|
| 15 Sep 2024 | Announcement | New Data Presented at ESMO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer |
| 04 Sep 2024 | Announcement | Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors |
| 26 Aug 2024 | Announcement | Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle |
| 26 Aug 2024 | Announcement | Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference |
| 06 Aug 2024 | Announcement | Veracyte Announces Second Quarter 2024 Financial Results |
| 17 Jul 2024 | Announcement | Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |